Myriad Genetics Posts Preliminary Results For Q4,09

Myriad Genetics anticipates reporting total molecular diagnostic revenue, which represents the bulk of the company’s revenue, of approximately $86 million for the fourth quarter of fiscal 2009, ending June 30.

Previously, the company expected total molecular diagnostic revenue for the full 2009 fiscal year to grow more than 48%, to approximately $330 million. The company is projecting that molecular diagnostic revenue for the fiscal year ending June 30, 2009 will be approximately $326 million, or a 46% increase over the prior fiscal year.

Myriad Genetics’ revenue results remain subject to review by its independent registered public accounting firm. The company expects to report final fourth quarter and full year financial results on August 25, 2009.